C-EPO: Ready for prime-time preconditioning?

Cerebrovascular Diseases

Volumn 19, Issue 4, 2005, Pages 272-273

  Kennedy, James ^a   Buchan, Alastair M ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID DERIVATIVE; CARBAMYLATING ERYTHROPOIETIN; ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANEMIA; ANTIINFLAMMATORY ACTIVITY; BRAIN INFARCTION PREVENTION; BRAIN ISCHEMIA; BRAIN PROTECTION; COGNITION; CONVALESCENCE; DIABETIC NEUROPATHY; DRUG EFFECT; HEMODIALYSIS; LONG TERM CARE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SHORT SURVEY; SPINAL CORD INJURY; THROMBOSIS;

ANIMALS; BRAIN ISCHEMIA; ERYTHROPOIETIN; HUMANS; ISCHEMIC PRECONDITIONING; NEUROPROTECTIVE AGENTS;

EID: 17844365595     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084140     Document Type: Short Survey

References (5)

1. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, et al: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:6741-6746.
2. Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-354.
3. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
4. Nissenson AR: Epoetin and cognitive function. Am J Kidney Dis 1992;20(suppl 1):21-24.
5. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.